These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 31804714)
1. Cutaneous crospovidone reaction secondary to subcutaneous injection of buprenorphine. Marka A; Hoyt BS; Dagrosa AT; Barton DT; Kim A; Linos K; Yan S J Cutan Pathol; 2020 May; 47(5):470-474. PubMed ID: 31804714 [TBL] [Abstract][Full Text] [Related]
2. Cutaneous Crospovidone: A Newly Described Foreign Body Due to Illicit Drug Abuse. Hoyt BS; Aaron DM; Yan S; Linos KD Am J Dermatopathol; 2019 Aug; 41(8):e84-e86. PubMed ID: 31335429 [TBL] [Abstract][Full Text] [Related]
3. Embolized crospovidone (poly[N-vinyl-2-pyrrolidone]) in the lungs of intravenous drug users. Ganesan S; Felo J; Saldana M; Kalasinsky VF; Lewin-Smith MR; Tomashefski JF Mod Pathol; 2003 Apr; 16(4):286-92. PubMed ID: 12692192 [TBL] [Abstract][Full Text] [Related]
4. Injection of oral medication into the skin confirmed by infrared spectroscopy. Flint RL; Gelman A; Chiricosta FM; Strausborger S; Lewin-Smith M; Cho S J Cutan Pathol; 2020 Nov; 47(11):1067-1072. PubMed ID: 32713055 [TBL] [Abstract][Full Text] [Related]
5. Penile and scrotal skin necrosis after injection of crushed buprenorphine tablets. Kluger N; Girard C; Guillot B; Bessis D Presse Med; 2010 May; 39(5):610-1. PubMed ID: 20303699 [No Abstract] [Full Text] [Related]
6. Cutaneous foreign body microemboli-induced occlusive vasculopathy: A complication of illicit intravenous injection of oral opioid tablets. Vu M; Wisell J; Wohltmann W J Cutan Pathol; 2021 Sep; 48(9):1173-1177. PubMed ID: 33934378 [TBL] [Abstract][Full Text] [Related]
7. Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder. Med Lett Drugs Ther; 2018 Feb; 60(1541):35-37. PubMed ID: 29485976 [No Abstract] [Full Text] [Related]
8. Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets. Feeney GF; Fairweather P Drug Alcohol Rev; 2003 Sep; 22(3):359-61. PubMed ID: 15385230 [TBL] [Abstract][Full Text] [Related]
9. Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions. Bouquié R; Wainstein L; Pilet P; Mussini JM; Deslandes G; Clouet J; Dailly E; Jolliet P; Victorri-Vigneau C PLoS One; 2014; 9(12):e113991. PubMed ID: 25474108 [TBL] [Abstract][Full Text] [Related]
10. Allergic contact dermatitis due to transdermal buprenorphine. Pérez-Pérez L; Cabanillas M; Loureiro M; Fernández-Redondo V; Labandeira J; Toribio J Contact Dermatitis; 2008 May; 58(5):310-2. PubMed ID: 18416765 [No Abstract] [Full Text] [Related]
11. An unusual case of livedoid and necrotic lesions in a drug addict. Pierre-Alexandre J; François le P; Abdellah S; Karim T; Christian de G; Frédérique C Am J Dermatopathol; 2007 Feb; 29(1):72-4. PubMed ID: 17284966 [TBL] [Abstract][Full Text] [Related]
12. Urticaria and anaphylaxis to povidone in a paracetamol preparation. Bergendorff O; Hansson C J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):573-4. PubMed ID: 17374012 [No Abstract] [Full Text] [Related]
13. [Povidone hypersensitivity--extremely unusual or underestimated? The pharmaceutic aid povidone was earlier not considered toxic or allergenic]. Ekman E; Werkström V; Vinge E; Hansson C Lakartidningen; 2007 Apr 25-May 1; 104(17):1318-9. PubMed ID: 17547277 [No Abstract] [Full Text] [Related]
14. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Pergolizzi JV; Scholten W; Smith KJ; Leighton-Scott J; Willis JC; Henningfield JE Acta Anaesthesiol Taiwan; 2015 Jun; 53(2):71-6. PubMed ID: 26205326 [TBL] [Abstract][Full Text] [Related]
15. A methadone user with anaemia, skeletal pain and altered appearance. Kaur P; Bergrem A; Gerlyng P; Reims HM; Leh S; Valeur J Tidsskr Nor Laegeforen; 2016 Jun; 136(10):925-9. PubMed ID: 27272371 [No Abstract] [Full Text] [Related]
16. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Frost M; Bailey GL; Lintzeris N; Strang J; Dunlop A; Nunes EV; Jansen JB; Frey LC; Weber B; Haber P; Oosman S; Kim S; Tiberg F Addiction; 2019 Aug; 114(8):1416-1426. PubMed ID: 31013390 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study. Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242 [TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243 [TBL] [Abstract][Full Text] [Related]
19. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758 [TBL] [Abstract][Full Text] [Related]
20. Anaphylaxis to polyvinylpyrrolidone in an analgesic preparation. Rönnau AC; Wulferink M; Gleichmann E; Unver E; Ruzicka T; Krutmann J; Grewe M Br J Dermatol; 2000 Nov; 143(5):1055-8. PubMed ID: 11069520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]